Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ RAD52 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA5119963
This item is not returnable.
View return policy
Description
Positive Control: Hela cell lysate, HL-60 cell lysate, human thyroid tissue, human colon carcinoma tissue, human liver carcinoma tissue, human spleen tissue, mouse liver tissue, rat spleen tissue. Subcellular Location: Nucleus.
DNA double-strand breaks can be generated by exposure to ionizing radiation or through endogenous cellular reactions. Double-strand breaks are generally thought to be repaired via one of two distinct mechanisms: homologous recombination (HR) or non-homologous end joining (NHEJ). Homologous recombination requires the activity of the members of the RAD52 epistasis group, which includeRAD50, RAD51, RAD52, RAD54, RDH54/TID1, RAD55, RAD57, RAD59, MRE11, and XRS2. RAD52 can catalyze strand annealing reactions, and can form oligomers that attach to ends of single-stranded DNA.
Specifications
RAD52 | |
Polyclonal | |
Unconjugated | |
RAD52 | |
DNA repair protein RAD52 homolog; RAD52; RAD52 homolog (S. cerevisiae); RAD52 homolog, DNA repair protein; Rad52yh; recombination protein RAD52; rhabdomyosarcoma antigen MU-RMS-40.23 | |
Rabbit | |
Affinity Chromatography | |
RUO | |
19365, 297561, 5893 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Immunohistochemistry (Paraffin), Western Blot | |
1 mg/mL | |
TBS with 0.2% BSA, 50% glycerol and 0.05% sodium azide; pH 7.4 | |
P43351, P43352 | |
RAD52 | |
Synthetic peptide within human RAD52 aa 331-380/418. | |
100 μL | |
Primary | |
Human, Mouse, Rat | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction